DTCA has grown so large that the average American television viewer spends more time watching prescription drug advertisements than they do with their family physician (Brownfield et al., 2004). Every developed country in the world, save the United States and New Zealand, prohibits direct-to-consumer pharmaceutical advertising and the fact that it is only allowed in these two countries brings into question its real motives towards the average consumer. The facts are, if you have watched any television during the last 15 years then you have heard more than likely heard the saying, “ask your doctor if ‘blank’ is right for you”. There are pro’s and con’s when it comes to DTCA. Proponents claim it benefits consumers with knowledge of various illnesses and the possible treatments available to them.
Any industry is not without its own isolated illegal and unethical behavior. The pharmaceutical industry has countless examples of these, which is why we are going to look in on some of the general practices that all the companies participate in and the ethical debate around them. The marketing practices of the pharmaceutical industry have a great deal of controversy around the technique used to promote and advertise their products. More than a third of pharmaceutical companies’ resources go into promotion and marketing. Annually, the industry spends nearly twice as much on marketing as it spends on research and development.
In some cases off-label uses often exceed the intended use, which in turn becomes very profitable for the pharmaceutical manufacturer. “In 2004, sales of the drug peaked at $2.7 billion. But that same year Pfizer was found to be urging physicians to prescribe Neurontin for off-label uses, which is illegal. As a result, the company had to pay $430 million in criminal fines and civilian penalties.” (Arellano, 2013). Since it would be beneficial to companies to get approval from the Federal Drug Administration (FDA), companies will conduct research studies on the effects of these other conditions.
IMPACT ON CANADAIN BUSINESSES What kind of an impact will the cap and trade system have on business? Is it good or bad for business? In the simplest terms, cap and trade is a market-based solution to an environmental problem. The government puts a cap on pollution (greenhouse gas emissions in this case) and allows businesses to figure out the most cost-effective way of keeping their combined pollution under the cap. However, within this broad framework, many details need to be worked out, and the costs and benefits to businesses will depend on how the government tackles these finer points (Horne, 2011).
Pharma Care Ethics and Corporate Responsibilities Andrea Staton Strayer University ELLEN KAPALKO May 25, 2015 Pharma Care Ethics and Corporate Responsibilities Numerous people do not know the full story about their pharmaceutical companies in place of a well-known problem involving unpublished influence, according to mounting the evidence. Often, medical journals that patronize research will make statements only "active" results leaving out the findings of false results where an original drug or wok experience may have been upheld more hurtful than help. The new study of the difficult points to hidden or misrepresentation for all sorts of conditions. Meanwhile, modern pharmaceutical companies like Pharma Care ethical treatment of workers in a foreign country factory is beyond cruel and cold-hearted. The large manufacturing facility in the African nation of Calabria, which is own by Pharma Care.
Prohibition versus Legalizing Medical Marijuana The use of alternative therapy is often criticized due to the lack of scientific testing and results in a strong argument of safety and efficacy. Studies show that forty percent of the general public is using some form of Complimentary Alternative Medicine (CAM) (Annas). Medical marijuana is also termed as alternative medicine, unconventional, complementary or integrative (Annas). The use of marijuana for medicinal purposes is gaining momentum because doctors have been prescribing medicinal marijuana to treat pain, nausea, severe weight loss, and vomiting which are side effects associated with chemotherapy and Acquired Immunodeficiency Syndrome (AIDS). Fifteen states have approved the use of medical marijuana.
Disability Statistics 43 million are disabled, about 17% of 250 million; almost 1 out of 5 persons are disabled given these figures. [Congressional Committee findings for ADA]. Other sources show higher figures. Largest minority group One third of disabled Americans are 65 or older. Out of 45 million, that means 15 million of them are seniors.
BP has been criticized and put under pressure by critics regarding corporate social responsibility, as Mother Jones Magazine listed BP as one of ten worst corporations in 2001 regarding environmental and human rights issues (Mokhiber & Weissman, 2001). Such accidents cost BP millions of dollars and corporate’s image distortion. For example, in 1999 BP paid approximately $22 million as charges in relation to illegal dumping of hazardous waste in Alaska (EPA, 1999). BP’s ‘Green’ image is supported in its corporate strategy as they follow proved technologies to enhance productivity with less impact on environment. According to BP’s 2006 annual review, 1.2 million tonnes of greenhouse gas reductions have been delivered in a number of projects during 2006.
Although this number is pretty low, US is still ranked highest among countries based on infant mortality rates within the OECD countries. If the US cannot take care of our babies then how can they take care of us? The US is currently deciding on whether to pass the healthcare reform bill, which seeks to expand health care coverage to the approximately 40 million Americans who are currently uninsured by lowering the cost of health care and making the system more efficient (OpenCongress). But sometimes austere actions need to be taken otherewise the purpose gets defeated and victory accompanies the opposition. And in this case Canada has won the race against the
Chapter one analyses Medtronic as a multinational enterprise by addressing”an initial screening of business environment including political environment, economics, culture etc. Medtronic’s competitiveness and abilities is analyzed through a combination of country specific advantages (CSAs) and firm specific advantages (FSAs) and is included in FSA/CSA Matrix and by addressing Porter’s four determinants. In chapter Two in-depth analysis of challenges and issues the company faces as well as risk management plan the company must undertake in a long run for reducing its operational risks. The last chapter is about developing a strategy for the successful operation of Medtronic as an MNE with an overview of IHRM, personal selection, training and development. Recommendations and suggestions for Medtronic on the level of involvement the company should take to increase the likelihood of long term success are included in the conclusion.